A 26-year-old female patient was admitted to the hospital with recurrent infection of the incision after resection of a back sebaceous cyst, and the pus culture showed Mycobacterium abscessus. Clinical pharmacists reviewed relevant guidelines and literature, analyzed and summarized drug selection, drug resistance, adverse drug reactions and coping strategies, sequential treatment plans and treatment courses, and assist physicians in formulating individualised anti-infective treatment plans. Initially imipenem, amikacin and azithromycin were given according to bacterial culture results. Secondly, according to the results of drug sensitivity, they were changed to tigecycline, amikacin and clarithromycin. Finally, due to the adverse drug reaction of tigecycline and the recurrence of sinus in the patient, and considering the possibility of imipenem and clarithromycin resistance, the anti-infection regimen was adjusted in time to cefoxitin, amikacin and azithromycin. During treatment, the clinical pharmacist monitors drug effectiveness and adverse reactions, combining pharmacy expertise with clinical practice. After the treatment, the patient improved and was discharged. After discharge, azithromycin and omacycline were successively given to continue anti-infection treatment, and the incision on the patient's back basically healed through follow-up. Clinical pharmacist involvement in Mycobacterium abscessus anti-infective drug selection can provide individualised drug regimens for patients, ensure the safety and effectiveness of medication for patients, and provide references for the treatment and management of similar patients.

1.Recchia D, Stelitano G, Stamilla A, et al. Mycobacterium abscessus infections in cystic fibrosis individuals: a review on therapeutic options[J]. Int J Mol Sci, 2023, 24(5): 4635. DOI: 10.3390/ijms24054635.

2.Fröberg G, Maurer FP, Chryssanthou E, et al. Towards clinical breakpoints for non-tuberculous mycobacteria-determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution[J]. Clin Microbiol Infect, 2023, 29(6): 758-764. DOI: 10.1016/j.cmi.2023. 02.007.

3.Alcaraz M, Edwards TE, Kremer L. New therapeutic strategies for Mycobacterium abscessus pulmonary diseases-untapping the mycolic acid pathway[J]. Expert Rev Anti Infect Ther, 2023, 21(8): 813-829. DOI: 10.1080/ 14787210.2023.2224563.

4.Cristancho-Rojas C, Varley CD, Lara SC, et al. Epidemiology of Mycobacterium abscessus[J]. Clin Microbiol Infect, 2024, 30(6): 712-717. DOI: 10.1016/j.cmi.2023.08.035.

5.刘盛盛, 唐神结. 《非结核分枝杆菌病诊断与治疗指南(2020年版)》解读[J]. 结核与肺部疾病杂志. 2021, 2(2): 108-115. [Liu SS, Tang SJ. Interpretation of the guideline for diagnosis and treatment of non-tuberculous mycobacteria disease (2020 edition)[J]. China Pharmacist, 2024, 2(2): 108-115.] DOI: 10.3969/j.issn.2096-8493. 2021.02.004.

6.Varley CD, Winthrop KL. Nontuberculous Mycobacteria: diagnosis and therapy[J]. Clin Chest Med, 2022, 43(1): 89-98. DOI: 10.1016/j.ccm.2021.11.007.

7.Yasen D, Liu C, Mei X, et al. Mycobacterium haemophilum infection with cutaneous involvement: two case reports and an updated literature review: Mycobacterium haemophilum skin infection[J]. J Dtsch Dermatol Ges, 2023, 21(11): 1291-1305. DOI: 10.1111/ddg.15163.

8.Griffith DE, Daley CL. Treatment of Mycobacterium abscessus pulmonary disease[J]. Chest, 2022, 161(1): 64-75. DOI: 10.1016/j.ccm.2023.06.010.

9.Dedrick RM, Smith BE, Cristinziano M, et al. Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant Mycobacterial disease[J]. Clin Infect Dis, 2023, 76(1): 103-112. DOI: 10.1093/cid/ciac453.

10.Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous Mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline[J]. Clin Infect Dis, 2020, 71(4): 905-913. DOI: 10.1093/cid/ciaa1125.

11.林振庭. 皮肤脓肿分枝杆菌感染3例临床分析并文献复习[D]. 沈阳: 中国医科大学, 2024. DOI: 10.27652/d.cnki.gzyku.2023.000443.

12.Choi H, Kim YI, Na CH, et al. Mycobacterium abscessus skin infection associated with shaving activity in a 75-year-old man[J]. Ann Geriatr Med Res, 2018, 22(4): 204-207. DOI: 10.4235/agmr.18.0034.

13.Tiong CW, Nack T, Tai AYC, et al. Medical management of atraumatic Mycobacterium abscessus cutaneous infection: a case report[J]. J Clin Tuberc Other Mycobact Dis, 2019, 17: 100132. DOI: 10.1016/j.jctube.2019.100132.

14.Cardenas DD, Yasmin T, Ahmed S. A rare insidious case of skin and soft tissue infection due to Mycobacterium abscessus: a case report[J]. Cureus, 2022, 14(6): e25725. DOI: 10.7759/cureus.25725.

15.Deng L, Luo YZ, Liu F, et al. Subcutaneous infection caused by Mycobacterium abscessus following cosmetic injections of botulinum toxin: a case report[J]. World J Clin Cases, 2022, 10(18): 6141-6147. DOI: 10.12998/wjcc.v10.i18.6141.

16.Choi J, Keen EC, Wallace MA, et al. Genomic analyses of longitudinal Mycobacterium abscessus isolates in a multicenter cohort reveal parallel signatures of in-host adaptation[J]. J Infect Dis, 2023, 228(3): 321-331. DOI: 10.1093/infdis/jiad187.

17.Yoshida S, Tsuyuguchi K, Kobayashi T, et al. Comparison of drug-susceptibility patterns and gene sequences associated with clarithromycin and azithromycin resistance in Mycobacterium abscessus complex isolates and evaluation of the accumulation of intrinsic macrolide resistance[J]. J Med Microbiol, 2021, 70(3). DOI: 10.1099/jmm.0.001326.

18.Richard M, Gutiérrez AV, Kremer L. Dissecting erm(41)-mediated macrolide-inducible resistance in Mycobacterium abscessus[J]. Antimicrob Agents Chemother, 2020, 64(2): e01879-19. DOI: 10.1128/AAC. 01879-19.

19.Lange K, Janßen S, Dimmers F, et al. [Nontuberculous mycobacterial infection after tattooing caused by Mycobacterium chelonae][J]. Dermatologie (Heidelb), 2023, 74(9): 711-714. DOI: 10.1007/s00105-023-05173-y.

20.Gopalaswamy R, Shanmugam S, Mondal R, et al. Of tuberculosis and non-tuberculous Mycobacterial infections-a comparative analysis of epidemiology, diagnosis and treatment[J]. J Biomed Sci, 2020, 27(1): 74. DOI: 10.1186/s12929-020-00667-6.

21.Rizzo AR, Moniri NH. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use[J]. BMC Infect Dis, 2022, 22(1): 874. DOI: 10.1186/s12879-022-07857-7.

22.Sakatoku Y, Okada Y, Takahashi Y, et al. A rare spontaneous breast abscess due to Mycobacterium chelonae: a case report[J]. Surg Case Rep, 2023, 9(1): 125. DOI: 10.1186/s40792-023-01706-8.

23.Sakoulas G, Nowak M, Geriak M. Omadacycline in treating community-based infections:a review and expert perspective[J]. Expert Rev Anti Infect Ther, 2023, 21(3): 255-265. DOI: 10.1080/14787210.2023.2174100.

24.Frizzell M, Carr E, Brust K. Omadacycline for treatment of Mycobacterium chelonae skin infection[J]. Proc (Bayl Univ Med Cent), 2020, 33(4): 610-611. DOI: 10.1080/08998280.2020.1792748.

25.Pearson JC, Dionne B, Richterman A, et al. Omadacycline for the treatment of Mycobacterium abscessus disease: a case series[J]. Open Forum Infect Dis, 2020, 7(10): ofaa415. DOI: 10.1093/ofid/ofaa415.

26.Lyu J, Jang HJ, Song JW, et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs[J]. Respir Med, 2011, 105(5): 781-787. DOI: 10.1016/j.rmed.2010.12.012.

27.Novosad SA, Beekmann SE, Polgreen PM, et al. Treatment of Mycobacterium abscessus infection[J]. Emerg Infect Dis, 2016, 22(3): 511-514. DOI: 10.3201/eid2203.150828.

28.Wallace RJ, Dukart G, Brown-Elliott BA, et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections[J]. J Antimicrob Chemother, 2014, 69(7): 1945-1953. DOI: 10.1093/jac/dku062.

29.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.